CodeMark | Minghao Technology Announces Completion of Tens of Millions of RMB in Series A Funding, Led by Source Code Capital

Minghao Technology, an innovative company focused on medical vision technology, has officially announced the completion of a Series A financing round of tens of millions of RMB, led by Source Code Capital.

This round of financing injects fresh momentum into Minghao Technology's growth, further advancing the expansion of the company's independently developed 5-Diopter Precision Fitting System and vision health solutions across both medical and consumer markets, while accelerating R&D innovation in ophthalmic medicine and vision science.

Since its founding, Minghao Technology has remained committed to innovation in ophthalmology and vision technology. Guided by customer vision needs, grounded in clinical ophthalmology, and supported by high-end precision manufacturing of optical lenses and advanced hard-coating processes, the company has gradually achieved notable success in the medical optometry field. Its core products span medical refractive correction solutions, the 5-Diopter Precision Fitting System, high-quality optical lenses, and optometry store SAAS systems — all industry-leading offerings that have earned high recognition from numerous experts. To date, the company's 5-Diopter Precision Fitting System and optical lens products have been deployed in nearly 300 medical institutions across 16 provinces and autonomous regions nationwide.

Zhu Xiao, Founder, Chairman and CEO of Minghao Technology, stated: "We are honored to have earned the trust and recognition of top-tier institutions in the healthcare sector through this Series A round. This year, Minghao Technology's fully independent innovation for slowing myopia progression in Chinese children and adolescents — the 5-Diopter Defocus Lens, branded as Diandian Sunshine — achieved encouraging results in clinical validation at Tongren Hospital. Its myopia control rate of up to 70% has received widespread affirmation and coverage by central media. Meanwhile, clinical studies targeting different ages, populations, and visual usage scenarios are underway at multiple renowned domestic ophthalmology hospitals. Going forward, we will continue focusing on developing vision health solutions for the global refractive error population. With the support of capital and the advantages of our technology platform, we will accelerate the R&D and commercialization of vision health technologies, bringing better visual solutions to consumers more quickly, fulfilling our mission — 'Discover, Make the World Clearer.'"

"I would also like to take this opportunity to welcome Professor Zhang Zuoming to Minghao Technology, where he will serve as Dean and Chief Scientist of the Minghao Vision Research Institute. Professor Zhang is the former Director of the Clinical Medicine Teaching and Research Section at the Aerospace Medicine Department of Air Force Medical University, and a review expert for projects under the National Natural Science Foundation, the Ministry of Science and Technology's international S&T cooperation programs, and military medical achievement awards. He has long been dedicated to teaching, research, and clinical work in ophthalmology and vision science. I am confident that with Professor Zhang's joining, we will be better positioned to realize Minghao Technology's vision of 'becoming the most trusted vision health company.'"

Kou Guan, Co-founder, Director and COO of Minghao Technology, stated: "We are grateful to top-tier investment institutions for recognizing Minghao Technology's early achievements and future potential. This financing round will provide strong support for further market expansion of our existing precision fitting system and high-quality optical lens product lines. At the same time, it will help us accelerate research and commercialization in vision science to meet more unmet vision health needs.

"Moreover, with the backing of our investors in this round, we will officially enter the consumer market and launch two brand initiatives: 'Wangshu Vision' and 'Muyu Alliance.' Wangshu Vision is positioned as a premium vision management service, applying all of Minghao Technology's vision health research to help consumers achieve the goal of 'Wangshu' — clear, comfortable sight. Muyu Alliance is positioned as a model innovation for selling high-value optical lenses, with the mission of 'getting good lenses on Chinese faces.' This will allow our domestic lens products, which rival international flagship lines, to reach more people at lower prices and with better service, building a 'new national brand' that shines."

Dr. Yuhao Zhang, Executive Director at Source Code Capital, stated: "Half of China's population faces refractive errors — the vision care industry is a massive sector addressing people's needs for healthy eyesight. Its preventive medicine characteristics place it between serious clinical settings and consumer scenarios, which also poses challenges for establishing complete product and industry standards. Minghao Technology is one of the few companies we've seen in this industry that is truly consumer-demand-oriented and validates efficacy through rigorous clinical standards. Its top-tier optical design and lens processing capabilities ensure the company can continue developing high-quality clinical-grade vision care products. We are pleased to participate in this round and look forward to seeing the company's products benefit consumers soon."